VivoSeq
Oncology

Cervical Carcinoma

38

Pipeline Programs↗

12

Active Trials↗

26

Companies Involved↗

Cervical Carcinoma is a moderately active landscape with 38 programs across 26 companies. The most active players are Johnson & Johnson, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Shandong New Time Pharmaceutical Co., LTD. 3 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

19/100

Mech. Concentration

11/100

Completion Rate

77/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1S

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

1 program

Phase 2S

Shandong New Time Pharmaceutical Co., LTD

1 program

Phase 2I

Iovance Biotherapeutics, Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2T

TCRCure Biopharma Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

61%

Small molecule

23 of 38 classified programs — the dominant modality here.

39%ALL OTHERSMonoclonal antibody1232%Cell therapy25%Peptide13%

Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 98% of 41 pipeline programs.

Analysis

Trial Status

30

clinical trials

Completed10 · 33%
Unknown status5 · 17%
Recruiting5 · 17%
Active, not recruiting4 · 13%
Terminated3 · 10%
Not yet recruiting2 · 7%
Other1 · 3%

Clinical Trials

Trial Activity

30 trials

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06241235·48 enrolled
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Recruiting·—·Phase 2·NCT07336147·45 enrolled
NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S04
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT07281430·500 enrolled
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Recruiting·IInstitut Claudius Regaud·Phase 3·NCT05581121·510 enrolled
A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT06535607·257 enrolled
NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S02
Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT06611553·500 enrolled
NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S03
Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT06611540·500 enrolled
Preliminary Descriptive Exploratory Pilot Study Research of Circulating Tumor Cells Released During Cervical Cancer Surgery
Active, not recruiting·UUniversity Hospital, Montpellier·Preclinical·NCT04770090·200 enrolled
A Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity-Modulated Radiation Therapy for Post-Operative Treatment of Endometrial or Cervical Cancers
Active, not recruiting·MMayo Clinic·Preclinical·NCT04567771·120 enrolled
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
Not yet recruiting·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT06333821·460 enrolled
Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study
Not yet recruiting·MMayo Clinic·Preclinical·NCT07662824·44 enrolled
Leveraging Project ECHO for Improved Cervical Cancer Screening in Ethiopia: An Implementation Study of Integrated HPV Selfsampling in HIV Care Centers
Enrolling by invitation·AAlbert Einstein College of Medicine·Preclinical·NCT07678047·60 enrolled
Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma
Completed·YYong Zhang,MD·Phase 2·NCT03086681·120 enrolled
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT06781073·118 enrolled
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma
Completed·UUniversity of California, San Diego·Phase 1·NCT01554410·35 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)